TY - JOUR T1 - Evaluation of patients treated by telemedicine in the COVID-19 pandemic by a private clinic in São Paulo, Brazil: A non-randomized clinical trial preliminary study JF - medRxiv DO - 10.1101/2021.11.05.21265569 SP - 2021.11.05.21265569 AU - Michelle Chechter AU - Gustavo Maximiliano Dutra da Silva AU - Thomas Gabriel Miklos AU - Marta Maria Kemp AU - Nilzio Antonio da Silva AU - Gabriel Lober AU - Marcela Ferreira Tavares Zanut AU - Rute Alves Pereira e Costa AU - Aline Pinheiro dos Santos Cortada AU - Luciana de Nazare Lima da Cruz AU - Paulo Macio Porto de Melo AU - Bruno Campello de Souza AU - Morton Aaron Scheinberg Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/05/2021.11.05.21265569.abstract N2 - Introduction As a result of the coronavirus disease 2019 (COVID-19) pandemic the year 2020 brought major changes on the delivery of health care and face to face physician patient communication was significantly reduced and the practice of remote telehealth care using computer technology is assuming a standard of care, particularly, with COVID-19 patients with attempts to reduce viral spread.Objective To describe the clinical practice experience using telemedicine towards COVID-19 and the respective clinical outcomes.Methods We performed a pilot open-label non-randomized, controlled clinical trial. The patients were divided into four groups, according severity of symptoms: (1) asymptomatic, (2) mild symptoms, (3) moderate symptoms and (4) severe symptoms, and were followed up for five days, counted from the beginning of the symptoms. A drug intervention was performed in group 3, for which the protocol followed as suggested by the International Pulmonology Society’s consensus for adults with moderate symptoms: first day (attack phase) hydroxychloroquine sulfate 400 mg 12/12h; second to fifth day (maintenance phase) 200 mg (half pill) 12/12h. The medication was associated with azithromycin 500mg once a day for five days. For children with moderate symptoms were used: hydroxychloroquine sulfate 6.5 mg/kg/dose every 12 hours in the first day and 3.25 mg/kg/dose every 12 hours from day 2 to 5. The therapeutic response was telemonitored. Group 4 patients were directly oriented to seek hospital care. During the use of the drugs, the patients were telemonitored daily.Results One hundred eighty-seven patients were seen with mean age of 37,6 years (±15,6). The most frequent symptom was cough (57,6%), followed by malaise (60,3%), fever (41,1%), headache (56,0%), muscle pain (51,1%). Of all the patients that sought telemedicine service in our center, 23% were asymptomatic despite contact with people with probable diagnostic of COVID-19; 29,4% reported mild symptoms, 43,9% moderate symptoms, and 3,7% severe symptoms. It was possible to observe in patients treated their symptoms of COVID-19 (group 3) with hydroxychloroquine and azithromycin for five days, presented statistically better improvement of the symptoms when compared to those that did not follow the protocol (p = 0.039). Three patients were hospitalized and discharged after recovery.Conclusions Our study showed that patients with COVID-19 who had delivery of health care through telemedicine initiated in early stages of the disease presented satisfactory clinical response, reducing the need of face-to-face consultations and hospitalizations. Our results indicate that the use of telemedicine with diagnosis and drug treatment protocols is a safe and effective strategy to reduce overload of health services and the exposure of healthcare providers and the general population to infected patients in a pandemic situation.Trial registration RBR-658khmHuman Research Ethics Committee number: 30246520.0.0000.0069Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical trial ID: 30246520.0.0000.0069 and Approval Number: 3.947.259Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of CENTRO DE REFERENCIA DA SAUDE DA MULHER - CRSM gave ethical approval for this work. Approval number: 3.947.259I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript ER -